There’s no cure for retinal vein occlusion. Your doctor can’t just unblock the retinal veins. Instead, treatment focuses on any complications and protecting your vision. In some cases ...

Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

EYLEA HD is a treatment for retinal vein occlusion (RVO) that allows for dosing every 8 weeks after initial monthly doses, potentially halving injections. What is the FDA's action date for EYLEA ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

and central retinal vein occlusion (CRVO), highlighting the risks of neovascularization and macular edema in BRVO and the greater treatment challenges presented by CRVO due to more extensive edema.

The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every 4-week (monthly ...

Occlusion of these terminal arterioles ... or even rare The vasculitic process typically affects the retinal arteries rather than the veins, and these signs are not specific to any type of ...

A recent study published in the Indian Journal of Ophthalmology has identified significant risk factors for postoperative ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...